HRP20130728T1 - 7-piperidinoalkyl-3,4-dihydroquinolone derivative - Google Patents

7-piperidinoalkyl-3,4-dihydroquinolone derivative

Info

Publication number: HRP20130728T1
Authority: HR; Croatia
Prior art keywords: piperidinoalkyl; dihydroquinolone; derivative; dihydroquinolone derivative
Prior art date: 2008-10-02

Application number

HRP20130728AT

Other languages

English (en)

Inventor

Kosuke Kanuma

Naoki Miyakoshi

Madoka Kawamura

Tsuyoshi Shibata

Original Assignee

Taisho Pharmaceutical Co., Ltd.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-10-02

Filing date

2013-08-01

Publication date

2013-10-11

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42073652&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20130728(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-08-01 Application filed by Taisho Pharmaceutical Co., Ltd. filed Critical Taisho Pharmaceutical Co., Ltd.

2013-10-11 Publication of HRP20130728T1 publication Critical patent/HRP20130728T1/hr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Psychiatry (AREA)
Hematology (AREA)
Pain & Pain Management (AREA)
Obesity (AREA)
Endocrinology (AREA)
Addiction (AREA)
Reproductive Health (AREA)
Anesthesiology (AREA)
Emergency Medicine (AREA)
Vascular Medicine (AREA)
Psychology (AREA)
Hospice & Palliative Care (AREA)
Child & Adolescent Psychology (AREA)
Urology & Nephrology (AREA)
Nutrition Science (AREA)
Gynecology & Obstetrics (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

HRP20130728AT 2008-10-02 2013-08-01 7-piperidinoalkyl-3,4-dihydroquinolone derivative HRP20130728T1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2008257072		2008-10-02
PCT/JP2009/067441 WO2010038901A1 (en)	2008-10-02	2009-09-30	7-piperidinoalkyl-3,4-dihydroquinolone derivative

Publications (1)

Publication Number	Publication Date
HRP20130728T1 true HRP20130728T1 (en)	2013-10-11

Family

ID=42073652

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HRP20130728AT HRP20130728T1 (en)	2008-10-02	2013-08-01	7-piperidinoalkyl-3,4-dihydroquinolone derivative

Country Status (29)

Country	Link
US (1)	US8461182B2 (hr)
EP (1)	EP2344471B1 (hr)
JP (1)	JP5541279B2 (hr)
KR (1)	KR20110067026A (hr)
CN (1)	CN102239159B (hr)
AR (1)	AR073727A1 (hr)
AU (1)	AU2009300607C1 (hr)
BR (1)	BRPI0925343A2 (hr)
CA (1)	CA2739513A1 (hr)
CL (1)	CL2011000734A1 (hr)
CO (1)	CO6321164A2 (hr)
CY (1)	CY1114165T1 (hr)
DK (1)	DK2344471T3 (hr)
ES (1)	ES2424393T3 (hr)
HK (1)	HK1159622A1 (hr)
HR (1)	HRP20130728T1 (hr)
IL (1)	IL212070A (hr)
MX (1)	MX2011003500A (hr)
MY (1)	MY154337A (hr)
NZ (1)	NZ592008A (hr)
PE (1)	PE20110410A1 (hr)
PL (1)	PL2344471T3 (hr)
PT (1)	PT2344471E (hr)
RS (1)	RS52964B (hr)
RU (1)	RU2498981C2 (hr)
SI (1)	SI2344471T1 (hr)
UA (1)	UA105187C2 (hr)
WO (1)	WO2010038901A1 (hr)
ZA (1)	ZA201102315B (hr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2011219467A (ja) *	2010-03-26	2011-11-04	Taisho Pharmaceutical Co Ltd	７−ピペリジノアルキル−３，４−ジヒドロキノロン誘導体を含有する医薬
US9512111B2 (en)	2010-11-08	2016-12-06	Lycera Corporation	N-sulfonylated tetrahydroquinolines and related bicyclic compounds for inhibition of RORγ activity and the treatment of disease
AU2013259737A1 (en)	2012-05-08	2014-10-02	Lycera Corporation	Tetrahydronaphthyridine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease
CA2872014A1 (en)	2012-05-08	2013-11-14	Lycera Corporation	Tetrahydro[1,8]naphthyridine sulfonamide and related compounds for use as agonists of ror.gamma. and the treatment of disease
EP2968210B1 (en) *	2013-03-12	2024-09-11	Bio-Pharm Solutions Co., Ltd.	Phenyl carbamate compounds for use in preventing or treating pediatric epilesy
US9809561B2 (en)	2013-12-20	2017-11-07	Merck Sharp & Dohme Corp.	Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease
WO2015095788A1 (en)	2013-12-20	2015-06-25	Merck Sharp & Dohme Corp.	2-ACYLAMIDOMETHYL AND SULFONYLAMIDOMETHYL BENZOXAZINE CARBAMATES FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE
US9783511B2 (en)	2013-12-20	2017-10-10	Lycera Corporation	Carbamate benzoxazine propionic acids and acid derivatives for modulation of RORgamma activity and the treatment of disease
EP3110429A4 (en)	2014-02-27	2018-02-21	Lycera Corporation	Adoptive cellular therapy using an agonist of retinoic acid receptor-related orphan receptor gamma & related therapeutic methods
US10189777B2 (en)	2014-05-05	2019-01-29	Lycera Corporation	Benzenesulfonamido and related compounds for use as agonists of RORγ and the treatment of disease
JP6728061B2 (ja)	2014-05-05	2020-07-22	リセラ・コーポレイションＬｙｃｅｒａＣｏｒｐｏｒａｔｉｏｎ	ＲＯＲγアゴニストとして用いるテトラヒドロキノリンスルホンアミド及び関連化合物ならびに疾患の治療
AU2016219183B2 (en)	2015-02-11	2020-06-11	Merck Sharp & Dohme Corp.	Substituted pyrazole compounds as RORgammaT inhibitors and uses thereof
CA2982847A1 (en)	2015-05-05	2016-11-10	Lycera Corporation	Dihydro-2h-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of ror.gamma. and the treatment of disease
MX2017016134A (es)	2015-06-11	2018-08-15	Lycera Corp	Aril dihidro-2h-benzo[b][1,4]oxazina sulfonamida y compuestos relacionados para uso como agonistas de rory y el tratamiento de enfermedad.
WO2017075178A1 (en)	2015-10-27	2017-05-04	Merck Sharp & Dohme Corp.	SUBSTITUTED BICYCLIC PYRAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
AU2016344118A1 (en)	2015-10-27	2018-05-10	Merck Sharp & Dohme Corp.	Heteroaryl substituted benzoic acids as rorgammat inhibitors and uses thereof
WO2017075182A1 (en)	2015-10-27	2017-05-04	Merck Sharp & Dohme Corp.	Substituted indazole compounds as rorgammat inhibitors and uses thereof
NZ746311A (en) *	2016-02-12	2022-08-26	Cytokinetics Inc	Tetrahydroisoquinoline derivatives

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP3335362B2 (ja) *	1995-09-15	2002-10-15	サノフィ―サンテラボ	キノレイン−２（１ｈ）−オン誘導体セロトニンアンタゴニスト
US7544690B2 (en)	2001-10-01	2009-06-09	Taisho Pharmaceutical Co., Ltd.	MCH receptor antagonists
KR20040048995A (ko) *	2001-10-25	2004-06-10	다케다 야쿠힌 고교 가부시키가이샤	퀴놀린 화합물
EP1464335A3 (en)	2003-03-31	2007-05-09	Taisho Pharmaceutical Co. Ltd.	Quinoline, tetrahydroquinoline and pyrimidine derivatives as mch antagonist
JP2006522109A (ja)	2003-03-31	2006-09-28	大正製薬株式会社	新規なキナゾリン誘導体及びそれらの使用に関連する治療方法
US20050209274A1 (en) *	2004-02-26	2005-09-22	Lynch John K	Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor
CA2558915A1 (en)	2004-03-30	2005-10-13	Taisho Pharmaceutical Co., Ltd.	Pyrimidine derivatives and methods of treatment related to the use thereof
JP2008514546A (ja)	2004-09-30	2008-05-08	大正製薬株式会社	ピリジン誘導体及びその使用に関連する治療法
WO2008044632A1 (fr)	2006-10-06	2008-04-17	Taisho Pharmaceutical Co., Ltd.	Dérivé de la 1-naphthyl alkylpipéridine

2009
- 2009-09-30 PL PL09817928T patent/PL2344471T3/pl unknown
- 2009-09-30 PE PE2011000810A patent/PE20110410A1/es not_active Application Discontinuation
- 2009-09-30 RU RU2011117161/04A patent/RU2498981C2/ru not_active IP Right Cessation
- 2009-09-30 NZ NZ592008A patent/NZ592008A/en not_active IP Right Cessation
- 2009-09-30 UA UAA201105428A patent/UA105187C2/uk unknown
- 2009-09-30 KR KR1020117007343A patent/KR20110067026A/ko not_active Application Discontinuation
- 2009-09-30 MX MX2011003500A patent/MX2011003500A/es active IP Right Grant
- 2009-09-30 AU AU2009300607A patent/AU2009300607C1/en not_active Ceased
- 2009-09-30 ES ES09817928T patent/ES2424393T3/es active Active
- 2009-09-30 SI SI200930738T patent/SI2344471T1/sl unknown
- 2009-09-30 DK DK09817928.6T patent/DK2344471T3/da active
- 2009-09-30 WO PCT/JP2009/067441 patent/WO2010038901A1/en active Application Filing
- 2009-09-30 CA CA2739513A patent/CA2739513A1/en not_active Abandoned
- 2009-09-30 BR BRPI0925343-2A patent/BRPI0925343A2/pt not_active IP Right Cessation
- 2009-09-30 EP EP09817928.6A patent/EP2344471B1/en active Active
- 2009-09-30 CN CN200980149091.2A patent/CN102239159B/zh not_active Expired - Fee Related
- 2009-09-30 JP JP2011513768A patent/JP5541279B2/ja not_active Expired - Fee Related
- 2009-09-30 MY MYPI2011001430A patent/MY154337A/en unknown
- 2009-09-30 RS RS20130370A patent/RS52964B/en unknown
- 2009-09-30 PT PT98179286T patent/PT2344471E/pt unknown
- 2009-09-30 US US13/122,281 patent/US8461182B2/en not_active Expired - Fee Related
- 2009-10-01 AR ARP090103798A patent/AR073727A1/es unknown
2011
- 2011-03-29 ZA ZA2011/02315A patent/ZA201102315B/en unknown
- 2011-03-30 CO CO11038711A patent/CO6321164A2/es active IP Right Grant
- 2011-03-31 IL IL212070A patent/IL212070A/en not_active IP Right Cessation
- 2011-04-01 CL CL2011000734A patent/CL2011000734A1/es unknown
2012
- 2012-01-04 HK HK12100046.0A patent/HK1159622A1/xx not_active IP Right Cessation
2013
- 2013-07-25 CY CY20131100633T patent/CY1114165T1/el unknown
- 2013-08-01 HR HRP20130728AT patent/HRP20130728T1/hr unknown

Also Published As

Publication number	Publication date
IL212070A (en)	2014-07-31
ES2424393T3 (es)	2013-10-01
AU2009300607C1 (en)	2014-08-07
EP2344471A1 (en)	2011-07-20
BRPI0925343A2 (pt)	2015-07-28
ZA201102315B (en)	2012-06-27
AU2009300607B2 (en)	2014-02-27
HK1159622A1 (en)	2012-08-03
SI2344471T1 (sl)	2013-11-29
WO2010038901A1 (en)	2010-04-08
EP2344471B1 (en)	2013-07-24
NZ592008A (en)	2011-12-22
CA2739513A1 (en)	2010-04-08
EP2344471A4 (en)	2012-05-30
AU2009300607A1 (en)	2010-04-08
CY1114165T1 (el)	2016-08-31
AR073727A1 (es)	2010-11-24
RU2011117161A (ru)	2012-11-10
KR20110067026A (ko)	2011-06-20
US20110178304A1 (en)	2011-07-21
MX2011003500A (es)	2011-05-02
JP5541279B2 (ja)	2014-07-09
US8461182B2 (en)	2013-06-11
CL2011000734A1 (es)	2011-09-23
MY154337A (en)	2015-05-29
PT2344471E (pt)	2013-08-01
PL2344471T3 (pl)	2013-12-31
CN102239159B (zh)	2014-06-25
DK2344471T3 (da)	2013-10-07
JP2012504549A (ja)	2012-02-23
RU2498981C2 (ru)	2013-11-20
UA105187C2 (uk)	2014-04-25
PE20110410A1 (es)	2011-07-02
RS52964B (en)	2014-02-28
CO6321164A2 (es)	2011-09-20
CN102239159A (zh)	2011-11-09
IL212070A0 (en)	2011-06-30

Publication	Publication Date	Title
HRP20130728T1 (en)	2013-10-11	7-piperidinoalkyl-3,4-dihydroquinolone derivative
SI2384326T1 (sl)	2014-06-30	Pirolo(2,3-d)pirimidinske spojine
EP2376493A4 (en)	2012-05-30	DIHYDROPYRIMIDOPYRIMIDINE DERIVATIVE
EP2380877A4 (en)	2012-06-27	PYRIDINE-3-CARBONSÄUREAMIDDERIVAT
IL206765A0 (en)	2010-12-30	4,5-dihydro-oxazol-2-yl-amine derivatives
EP2376494A4 (en)	2012-07-11	DIHYDROPYRIMIDOPIRYMIDINE DERIVATIVES
EP2331543A4 (en)	2013-06-19	3-DÉSAZANEPLANOCINE DERIVATIVES
HK1158189A1 (en)	2012-07-13	Morpholinopurine derivative
EP2291078A4 (en)	2011-08-24	OXAZOLBENZIMIDAZOLDERIVATE
EP2269993A4 (en)	2011-04-20	2-aminoquinazoline DERIVATIVE
EP2279532A4 (en)	2011-07-27	OXAZOLBENZIMIDAZOLDERIVATE
IL208623A0 (en)	2010-12-30	Cyclopentylacrylamide derivative
IL206875A0 (en)	2010-12-30	Bicycloamine derivative
ZA201006992B (en)	2011-06-29	Hydroxyquinoxalinecarboxamide derivative
EP2292613A4 (en)	2012-05-09	DIHYDROINDOLINONDERIVATE
SI2266990T1 (sl)	2013-01-31	Spojina 3-fenilpirazolo(5,1-b)tiazola
EP2248811A4 (en)	2011-08-03	2-OXOCHROMENE DERIVATIVE
IL212683A0 (en)	2011-07-31	Biphenylacetamide derivative
ZA201005346B (en)	2011-11-30	3,8-diaminotetrahydroquinoline derivative
EP2332925A4 (en)	2014-03-26	NOVEL DIHYDROTRIAZINE DERIVATIVE
EP2328892A4 (en)	2011-09-07	Oxo-tetrahydrofuran-2-YL-benzimidazole derivative
HK1206742A1 (en)	2016-01-15	Aminopropylidene derivative
GB0810164D0 (en)	2008-07-09	Wedge-dek, shower-floor gradient-former
GB0811138D0 (en)	2008-07-23	.
GB0808831D0 (en)	2008-06-18	.